4D Molecular Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
4D Molecular Therapeutics's earnings have been declining at an average annual rate of -22.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 6% per year.
Belangrijke informatie
-22.1%
Groei van de winst
29.3%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | 6.0% |
Rendement op eigen vermogen | -18.7% |
Nettomarge | -543.5% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
Oct 044D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 104D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11Opbrengsten en kosten
Hoe 4D Molecular Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 20 | -110 | 41 | 0 |
31 Mar 24 | 20 | -105 | 39 | 0 |
31 Dec 23 | 21 | -101 | 36 | 0 |
30 Sep 23 | 22 | -96 | 34 | 0 |
30 Jun 23 | 2 | -111 | 33 | 0 |
31 Mar 23 | 2 | -110 | 33 | 0 |
31 Dec 22 | 3 | -107 | 33 | 0 |
30 Sep 22 | 2 | -105 | 32 | 0 |
30 Jun 22 | 3 | -102 | 32 | 0 |
31 Mar 22 | 17 | -81 | 31 | 0 |
31 Dec 21 | 18 | -71 | 28 | 0 |
30 Sep 21 | 17 | -67 | 28 | 0 |
30 Jun 21 | 23 | -52 | 23 | 0 |
31 Mar 21 | 12 | -60 | 19 | 0 |
31 Dec 20 | 14 | -57 | 17 | 0 |
30 Sep 20 | 17 | -52 | 16 | 0 |
30 Jun 20 | 10 | -61 | 16 | 0 |
31 Mar 20 | 8 | -54 | 15 | 0 |
31 Dec 19 | 7 | -49 | 14 | 0 |
30 Sep 19 | 9 | -35 | 10 | 0 |
30 Jun 19 | 13 | -21 | 9 | 0 |
31 Mar 19 | 14 | -15 | 8 | 0 |
31 Dec 18 | 14 | -10 | 6 | 0 |
31 Dec 17 | 6 | -11 | 3 | 0 |
Kwaliteitswinsten: FDMT is currently unprofitable.
Groeiende winstmarge: FDMT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: FDMT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.
Versnelling van de groei: Unable to compare FDMT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: FDMT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: FDMT has a negative Return on Equity (-18.68%), as it is currently unprofitable.